Cortes, J. E., Baccarani, M., Guilhot, F., Druker, B. J., Branford, S., Kim, D., . . . Hughes, T. P. (2010). Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study. J Clin Oncol.

Cortes, Jorge E., et al. "Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 Mg Versus 800 Mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study." J Clin Oncol 2010.

Cortes, Jorge E., et al. "Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 Mg Versus 800 Mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study." J Clin Oncol 2010.